慢性乙型肝炎的免疫治疗研究进展*

doi:10.3969/j.issn.1672-5069.2016.04.032

摘要/Abstract

摘要： 临床上应用的抗乙型肝炎病毒（HBV）药物主要有干扰素和核苷（酸）类似物两类,在大多数慢性HBV感染者即使经过长期的抗病毒治疗仍不能彻底清除病毒。感染的控制和病毒的清除有赖于机体的免疫系统。感染慢性化与机体特异性免疫功能,尤其是细胞免疫功能低下密切相关。通过增强抗HBV感染的免疫治疗是被人们寄予厚望的一种治疗策略。目前研究的热点主要包括免疫激动剂、特异性细胞毒性T淋巴细胞（CTL）负调节分子阻断剂、特异性CTL调节分子激动剂或佐剂、治疗性疫苗、特异性T细胞受体（TCR）转基因技术、携带嵌合抗原受体的T细胞和多糖类物质等,本文对近年来这方面的研究进展进行了综述。

关键词: 慢性乙型肝炎, 免疫治疗, 进展

Abstract: There are two categories of antiviral agents that have been commonly used in treatment of patients with chronic hepatitis B,e.g. interferons and nucleos（t）ide analogues. Most patients fail to obtain eradication of HBV even receiving a long-term treatment. Disease control and viral clearance depend on the host’s immune responses,which is closely associated with specific-immunity,especially cellular immunity. Strategies of immunotherapies to boost or restore the virus-specific immune response of patients with chronic hepatitis B virus infection have been proposed for curing persistent infections. Currently,researches on immunotherapies focused on Toll-like receptors（TLR） agonists,negative immunomodulatory molecules of cytotoxic T lymphocyte（CTL）,CTL agonists,therapeutic vaccinations,specific T cell receptor（TCR） transgenic technology,chimeric antigen receptor T （CAR-T）cells,small molecule,etc. This review summarizes the recent progress in the above researches.

Key words: Chronic hepatitis B, Immune therapy, Progress

乔艳综述, 徐东平, 李进审校. 慢性乙型肝炎的免疫治疗研究进展^*[J]. 实用肝脏病杂志, 2016, 19(4): 493-496.

Qiao Yan, Xu Dongping, Li Jin. Immuno-therapy for chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(4): 493-496.

参考文献

[1] You CR,Lee SW,Jang JW,et al. Update on hepatitis B virus infection. World J Gastroenterol,2014,20（37）:13293-13305.
[2] Liang X,Bi S,Yang W,et al,Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine,2009,27（47）:6550-6557.
[3] Broering R,Lu M,Schlaak JF. Role of Toll-like receptors in liver health and disease. Clin Sci （Lond）,2011,121（10）:415-426.
[4] Guo H,Jiang D,Ma D,et al. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol,2009,83（2）:847-858.
[5] Lanford RE,Guerra B,Chavez D,et al. GS-9620,an oral agonist of Toll-like receptor-7,induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology,2013,144:1508-1517.
[6] Lopatin U,Wolfgang G,Tumas D,et al. Safety, pharmacokinetics and pharmacodynamics of GS-9620,an oral Toll-like receptor 7 agonist. Antivir Ther,2013,18:409-418.
[7] Gane EJ,Lim YS,Gordon SC. et al. The oral toll-like receptor-7 agonist gs-9620 in patients with chronic hepatitis B virus infection. Hepatology,2015,63,320-328.
[8] Sablan BP,Kim DJ,Barzaga NG,et al. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine,2012,30:2689-2696.
[9] Halperin SA,Ward B,Cooper C,et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyri-bonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. Vaccine,2012,30:2556-2563.
[10] Zhang E,Lu M. Toll-like receptor（TLR）-mediated innate immune responses in the control of hepatitis B virus （HBV） infection. Med Microbiol Immunol,2015,204:11-20.
[11] Kapoor R,Kottilil S. Strategies to eliminate HBV infection. Fut Virol,2014,9（6）:565-585.
[12] Peng GP,Li SP,Wu W,et al. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol,2008,45:963-970.
[13] Tzeng HT,Tsai HF,Liao HJ,et al. PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model. PLoS One,2012,7（6）:e39179.
[14] Yu Y,Wu H,Tang Z,et al. CTLA4 silencing with siRNA promotes deviation of Th1/Th2 in chronic hepatitis B patients. Cell Mol Immunol,2009,6（2）:123-127.
[15] Schurich A,Khanna P,Lopes AR,et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology,2011,53（5）:1494-1503.
[16] Wu W,Shi Y,Li S,et al. Blockade of Tim-3 signaling restores the virus-specific CD8 + T-cell response in patients with chronic hepatitis B. Eur J Immunol,2012,42（5）:1180-1191.
[17] Nebbia G,Peppa D,Schurich A,et al. Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection . PLoS One,2012,7（10）:647-648.
[18] Ju Y,Hou N,Meng J,et al. T cell immunoglobulin and mucin-domain-containing molecule-3 （Tim-3） mediates natural killer cell suppression in chronic hepatitis B. J Hepatol,2010,52（3）:322-329.
[19] 童新灯,李敏,胡国信,等. 慢性乙型肝炎患者外周血IL-7与细胞免疫的关系. 中国热带医学,2014,8:912-914.
[20] Mackall CL,Fry TJ,Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol,2011,11（5）:330-343.
[21] Publicover J,Goodsell A,Nishimura S,et al. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J Clin Invest,2011,121（3）:1154-1162.
[22] Gaggar A,Coeshott C,Apelian D,et al. Safety, tolerability and immunogenicity of GS-4774,a hepatitis B virus-specific therapeutic vaccine,in healthy subjects:a randomized study. Vaccine,2014,32:4925-4931.
[23] Martin P,Dubois C,Jacquier E,et al. TG1050,a viral-vector based immunotherapeutic designed to treat chronic hepatitis B induces immunoresponses with properties similar to those displayed by HBV resolving patients and has an early antiviral effect in a HBV tolerant model. Hepatology,2013,57:224-233.
[24] Spellman M,Martin JT. Treatment of chronic hepatitis B infection with DV-601,a therapeutic vaccine. J Hepatol,2011,54（Suppl 1）: S302.
[25] Lobaina Y,Hardtke S,Wedemeyer H,et al. In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. Mol Immunol,2015,63:320-327.
[26] Scott-Algara D,Mancini-Bourgine M,Fontaine H,et al. Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination. PLoS One,2010,5（1）:e8761.
[27] Yang SH,Lee CG,Park SH,et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers:a proof-of-concept study. Gene Ther,2006,13（14）:1110-1117.
[28] Yang FQ,Yu YY,Wang GQ,et al. A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy. J Viral Hepat,2012,19（8）:581-593.
[29] Inchauspé G1,Michel ML. Vaccines and immunotherapies against hepatitis B and hepatitis C viruses. J Viral Hepat,2007,14（1）:97-103.
[30] Michel M L,Bourgine M,Fontaine H,et al. Therapeutic vaccines in treating chronic hepatitis B:the end of the beginning or the beginning of the end Mol Ther Nucl Acids,2015,204（1）:121-129.
[31] 吴静,王琳,刘妍,等. 转基因表达乙型肝炎病毒抗原特异性细胞毒性T淋巴细胞受体的研究. 细胞与分子免疫学杂志,2013,29（5）:453-487.
[32] Koh S,Shimasaki N,Suwanarusk R,et al. A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol Ther Nucl Acids,2013,2（8）:e114.
[33] Qasim W,Brunetto M,Gehring AJ,et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells,targeting HBsAg in a liver transplant patient. J Hepatol,2015,62（2）:486491.
[34] Gill S,June CH. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev,2015,263（1）:6889.
[35] Bohne F,Chmielewski M,Ebert G,et al. T cells redirected against hepatitis B virus surface proteins eliminate infecdted hepatocytes. Gastroenterology,2008,134（1）:239-247.
[36] Sadelain M,Brentjens R,Riviere I. The basic principles of chimeric antigen receptor design. Cancer Disco,2013,3（4）: 388-398.
[37] 刘小燕,李朝品,王克霞. 多糖抗乙型肝炎病毒作用的研究进展. 中国病原生物学杂志,2014,9:845-851.
[38] 陈玉琴,吴群,张义翠,等. 阿德福韦酯联合香菇多糖治疗慢性乙型肝炎疗效观察. 医学理论与实践,2012,4:383-384.

慢性乙型肝炎的免疫治疗研究进展^*

Immuno-therapy for chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[6]	杨东亮, 刘嘉, 吴珺, 郑昕. 肝脏免疫学研究若干进展与挑战[J]. 实用肝脏病杂志, 2019, 22(5): 609-612.
[7]	杜科业, 杨东亮, 刘嘉. 慢性乙型肝炎与调节性T细胞研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 613-616.
[8]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[9]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[10]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[11]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[12]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[13]	李高明, 吕必华. 菖郁逍遥散治疗慢性乙型肝炎伴抑郁患者负性情绪和中医证候积分的变化^*[J]. 实用肝脏病杂志, 2019, 22(4): 498-501.
[14]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[15]	闫瑞斌, 马淑梅, 卓玛, 乔志忠, 刘潇. 慢性乙型肝炎患者血清MMP-2和TIMP-2水平及超声检查指标评估肝纤维化分期意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 506-509.